Global Access Program

Committed to Viral Hepatitis


Hepatitis B and C are among the most common viral infections in the world. In 2017, at least 263 million people worldwide were carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.1,2

 [WC2]Added in people to clarify “what or who” are the carriers 

95% of people living with viral

hepatitis do not know it.


In 2016, the World Health Assembly adopted WHO’s first
“Global Health Sector Strategy on viral hepatitis,”
with the elimination of viral hepatitis as a public
health threat by 2030.


Globally, 263 million

persons are infected

90% reduction in new cases of chronic hepatitis B and C by 2030

72 countries projected to meet the 2030 target
of ≤0.1% HBsAg prevalence among 5-Year-Olds

Egypt woman

Roche committed to the elimination of hepatitis


To advance global efforts and eliminate viral hepatitis, Roche is committed to this motivational program underscoring our ongoing efforts to provide life-saving diagnostics, and supports governments aiming to cure people of hepatitis.

Roche is a leader in viral load testing and is dedicated to enabling improved patient management by delivering innovative, high-quality diagnostic solutions where they are needed most. Through its Global Access Program, Roche worked with Egypt’s government officials and healthcare agencies to provide the country with robust and dependable HCV diagnostic solutions to help Egypt manage and achieve its ambitious goal.

 Read More about high-quality diagnostic solutions in Egypt

Sign up to receive regular updates about the Global Access Program.
Contact us



  1. World Health Organization. Hepatitis C Fact Sheet Updated July 2016. Last accessed July 2016 at
  2. World Health Organization. Global Hepatitis Report 2017. Last accessed May 2017 at
  3. World Health Organization. World Hepatitis Day. Last accessed July 2016 at
  4. Polaris Observatory Collaborators. Lancet Gastroenterol Hepatol. 2018